EPS for Opko Health, Inc. (OPK) Expected At $-0.08

February 17, 2018 – By Ellis Scott

Investors sentiment increased to 1.14 in Q3 2017. Its up 0.11, from 1.03 in 2017Q2. It is positive, as 19 investors sold Opko Health, Inc. shares while 58 reduced holdings. 25 funds opened positions while 63 raised stakes. 119.76 million shares or 0.19% less from 119.98 million shares in 2017Q2 were reported.
Financial Bank Of Montreal Can, Ontario – Canada-based fund reported 1.06 million shares. Davenport And Company Limited Liability Company reported 60,100 shares. 343,758 are owned by Credit Suisse Ag. Qs Invsts Ltd Liability has 6,200 shares. Highlander Capital Mngmt Limited Liability stated it has 0.01% of its portfolio in Opko Health, Inc. (NASDAQ:OPK). California-based Aperio Group Ltd has invested 0% in Opko Health, Inc. (NASDAQ:OPK). Profund Advsrs invested in 150,505 shares or 0.04% of the stock. Principal Fincl Gru stated it has 0% in Opko Health, Inc. (NASDAQ:OPK). Toronto Dominion Bancorp, a Ontario – Canada-based fund reported 26 shares. Blair William Company Il holds 0% in Opko Health, Inc. (NASDAQ:OPK) or 15,440 shares. Ami Asset Mngmt has invested 0.01% in Opko Health, Inc. (NASDAQ:OPK). 97,092 were reported by Hightower Advsr Ltd Liability. Psagot Invest House Limited holds 0.01% of its portfolio in Opko Health, Inc. (NASDAQ:OPK) for 25,029 shares. 1.33M were reported by Weiss Multi. New York-based D E Shaw & has invested 0% in Opko Health, Inc. (NASDAQ:OPK).

Since August 16, 2017, it had 18 insider purchases, and 0 insider sales for $6.49 million activity.

Analysts expect Opko Health, Inc. (NASDAQ:OPK) to report $-0.08 EPS on March, 7.They anticipate $0.04 EPS change or 100.00 % from last quarter’s $-0.04 EPS. After having $-0.08 EPS previously, Opko Health, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.78% or $0.11 during the last trading session, reaching $3.85. About 2.46M shares traded. Opko Health, Inc. (NASDAQ:OPK) has declined 32.62% since February 17, 2017 and is downtrending. It has underperformed by 49.32% the S&P500.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company has market cap of $2.15 billion. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. It currently has negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

More recent Opko Health, Inc. (NASDAQ:OPK) news were published by: Fool.com which released: “Could Opko Health Inc. Be a Millionaire-Maker Stock?” on January 30, 2018. Also Globenewswire.com published the news titled: “OPKO Health Announces Leadership Changes at BioReference Laboratories” on January 26, 2018. Benzinga.com‘s news article titled: “Benzinga’s Insider Buys Of The Week: BeiGene, Opko Health And More” with publication date: January 27, 2018 was also an interesting one.